Infliximab Therapy and the Central Nervous Demyelination in Patients with Kawasaki Disease

Autor:	Ryoko Nakamura, Akira Mizushima, Wataru Shimabukuro, Mamie Watanabe, Yuichiro Sugitani, Yuka Sagara, Miwa Yoshino, Masahiko Joo, Yasuhiko Takahashi, Jun Muneuchi, Toru Yoneda
Rok vydání:	2019
Předmět:	Male Microbiology (medical) Infliximab therapy medicine.medical_specialty Computed Tomography Angiography Mucocutaneous Lymph Node Syndrome 03 medical and health sciences 0302 clinical medicine 030225 pediatrics medicine Humans Brain magnetic resonance imaging In patient 030212 general & internal medicine medicine.diagnostic_test Tumor Necrosis Factor-alpha business.industry Immunoglobulins Intravenous Infant Magnetic resonance imaging equipment and supplies medicine.disease Magnetic Resonance Imaging Infliximab Infectious Diseases Antirheumatic Agents Child Preschool Pediatrics Perinatology and Child Health Female Kawasaki disease Radiology business human activities Biomarkers Demyelinating Diseases Follow-Up Studies medicine.drug
Zdroj:	Pediatric Infectious Disease Journal. 38:e185-e187
ISSN:	0891-3668
Popis:	We performed brain magnetic resonance imaging in 14 patients with Kawasaki disease who were treated with infliximab (IFX) at 56 months of age (32-62 months of age) and 23 months (5-35 months) after IFX therapy. Magnetic resonance imaging showed no finding of the central nervous demyelination. IFX therapy is not related to central nervous demyelination in patients with Kawasaki disease.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dd40a43c252bb104d53b79355f453e5 https://doi.org/10.1097/inf.0000000000002296 Zobrazit plný text záznamu